Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Rinke et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69d6c32e8dca315383ed8dae — DOI: https://doi.org/10.1200/jco.2009.22.8510

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Octreotide, a Somatostatin Analogue, Mediates Its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression· 2006 · 211 citations
2. Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma· 1992 · 974 citations
3. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors a prospective phase II study in 24 patients· 1993 · 258 citations
4. Method for Dissection of Mesenteric Metastases in Mid‐gut Carcinoid Tumors· 2000 · 153 citations
5. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.· 2002 · 446 citations